



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C07C 405/00 // A61K 31/557		A1	(11) International Publication Number: WO 00/51980 (43) International Publication Date: 8 September 2000 (08.09.00)
<p>(21) International Application Number: PCT/US00/05301</p> <p>(22) International Filing Date: 29 February 2000 (29.02.00)</p> <p>(30) Priority Data: 60/122,924 5 March 1999 (05.03.99) US</p> <p>(71) Applicant (for all designated States except US): THE PROCTER & GAMBLE COMPANY [US/US]; One Procter & Gamble Plaza, Cincinnati, OH 45202 (US).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (for US only): deLONG, Mitchell, Anthony [US/US]; 8084 Tyler's Circle, West Chester, OH 45069 (US). SOPER, David, Lindsey [US/US]; 12075 Brisben Place, Cincinnati, OH 45249 (US). WOS, John, August [US/US]; 8505 Harperpoint Drive, Cincinnati, OH 45249 (US). DE, Biswanath [US/US]; 11269 Comell Woods Drive, Cincinnati, OH 45241 (US).</p> <p>(74) Agents: REED, T., David et al.; The Procter & Gamble Company, 5299 Spring Grove Avenue, Cincinnati, OH 45217-1087 (US).</p>		<p>(81) Designated States: AE, AL, AM, AT, AT (Utility model), AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, CZ (Utility model), DE, DE (Utility model), DK, DK (Utility model), DM, EE, EE (Utility model), ES, FI, FI (Utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (Utility model), SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</p>	
<p>(54) Title: C₁₆ UNSATURATED FP-SELECTIVE PROSTAGLANDINS ANALOGS</p> <p style="text-align: center;"> (I) </p>			
<p>(57) Abstract</p> <p>The invention provides novel PGF analogs. In particular, the present invention relates to compounds having a structure according to formula (I), wherein R₁, R₂, X and Z are defined below. This invention also includes optical isomers, diastereomers and enantiomers of formula (I), and pharmaceutically-acceptable salts, biohydrolyzable amides, esters, and imides thereof. The compounds of the present invention are useful for the treatment of a variety of diseases and conditions, such as bone disorders. Accordingly, the invention further provides pharmaceutical compositions comprising these compounds. The invention still further provides methods of treatment for bone disorders using these compounds or the compositions containing them.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Morawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SL	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						


C₁₆ UNSATURATED FP-SELECTIVE PROSTAGLANDINS ANALOGS

TECHNICAL FIELD

The subject invention relates to certain novel analogs of the naturally occurring prostaglandins. Specifically, the subject invention relates to novel Prostaglandin F analogs. The subject invention further relates to methods of using said novel Prostaglandin F analogs. Preferred uses include methods of treating bone disorders and glaucoma.

BACKGROUND OF THE INVENTION

Naturally occurring prostaglandins (PGA, PGB, PGE, PGF, and PGI) are C-20 unsaturated fatty acids. PGF_{2 α} , the naturally occurring Prostaglandin F in humans, is characterized by hydroxyl groups at the C₉ and C₁₁ positions on the alicyclic ring, a cis-double bond between C₅ and C₆, and a trans-double bond between C₁₃ and C₁₄. Thus PGF_{2 α} has the following formula:



PGF_{2α}

Analogs of naturally occurring Prostaglandin F have been disclosed in the art. For example, see U.S. Patent No. 4,024,179 issued to Bindra and Johnson on May 17, 1977; German Patent No. D1-002,460,990 issued to Beck, Lerch, Seeger, and Teulel published on July 1, 1976; U.S. Patent No. 4,128,720 issued to Hayashi, Kori, and

5 Miyake on December 5, 1978; U.S. Patent No. 4,011,262 issued to Hess, Johnson, Bindra, and Schaaf on March 8, 1977; U.S. Patent No. 3,776,938 issued to Bergstrom and Sjovall on December 4, 1973; P.W. Collins and S. W. Djuric, "Synthesis of Therapeutically Useful Prostaglandin and Prostacyclin Analogs", Chem. Rev. Vol. 93 (1993), pp. 1533-1564; G. L. Bundy and F. H. Lincoln, "Synthesis of 17-Phenyl-18,19,20-
10 Trinorprostaglandins: I. The PG₁ Series", Prostaglandins, Vol. 9 No. 1 (1975), pp. 1-4; W. Bartman, G. Beck, U. Lerch, H. Teufel, and B. Scholkens, "Luteolytic Prostaglandins: Synthesis and Biological Activity", Prostaglandins, Vol. 17 No. 2 (1979), pp. 301-311; C. Liljebris, G. Selen, B. Resul, J. Sternschantz, and U. Hacksell, "Derivatives of 17-Phenyl-18,19,20-trinorprostaglandin F_{2α} Isopropyl Ester: Potential Antiglaucoma Agents",
15 Journal of Medicinal Chemistry, Vol. 38 No. 2 (1995), pp. 289-304.

Naturally occurring prostaglandins are known to possess a wide range of pharmacological properties. For example, prostaglandins have been shown to: relax smooth muscle, which results in vasodilatation and bronchodilatation, to inhibit gastric acid secretion, to inhibit platelet aggregation, to reduce intraocular pressure, and to
20 induce labor. Although naturally occurring prostaglandins are characterized by their activity against a particular prostaglandin receptor, they generally are not specific for any one prostaglandin receptor. Therefore, naturally-occurring prostaglandins are known to cause side effects such as inflammation, as well as surface irritation when administered systemically. It is generally believed that the rapid metabolism of the naturally occurring
25 prostaglandins following their release in the body limits the effects of the prostaglandin to a local area. This effectively prevents the prostaglandin from stimulating prostaglandin receptors throughout the body and causing the effects seen with the systemic administration of naturally occurring prostaglandins.


30 Prostaglandins, especially prostaglandins of the E series (PGE), are known to be potent stimulators of bone resorption. PGF_{2α} has also been shown to be a stimulator of bone resorption but not as potent as PGE₂. Also, it has been demonstrated the PGF_{2α} has little effect on bone formation as compared to PGE₂. It has been suggested that some of the effects of PGF_{2α} on bone resorption, formation and cell replication may be mediated by an increase in endogenous PGE₂ production.

35 In view of both the wide range of pharmacological properties of naturally occurring prostaglandins and of the side effects seen with the systemic administration of these naturally occurring prostaglandins, attempts have been made to prepare analogs to the naturally occurring prostaglandins that are selective for a specific receptor or receptors. A number of such analogs have been disclosed in the art. Though a variety

5 of prostaglandin analogs have been disclosed, there is a continuing need for potent, selective prostaglandin analogs for the treatment of a variety of diseases and conditions.

SUMMARY OF THE INVENTION

The invention provides novel PGF analogs. In particular, the present invention relates to compounds having a structure according to the following formula:



Formula A

wherein R_1 , R_2 , X , and Z are defined below.

15 This invention also includes optical isomers, diastereomers and enantiomers of the formula above, and pharmaceutically-acceptable salts, biohydrolyzable amides, esters, and imides thereof.

The compounds of the present invention are useful for the treatment of a variety of diseases and conditions, such as bone disorders and glaucoma. Accordingly, the invention further provides pharmaceutical compositions comprising these compounds. The invention still further provides methods of treatment for bone disorders and glaucoma using these compounds or the compositions containing them.

DETAILED DESCRIPTION OF THE INVENTION

25

Terms and Definitions

"Alkyl" is a saturated or unsaturated hydrocarbon chain having 1 to 18 carbon atoms, preferably 1 to 12, more preferably 1 to 6, more preferably still 1 to 4 carbon atoms. Alkyl chains may be straight or branched. Preferred branched alkyl have one or two branches, preferably one branch. Preferred alkyl are saturated. Unsaturated alkyl have one or more double bonds and/or one or more triple bonds. Preferred unsaturated alkyl have one or two double bonds or one triple bond, more preferably one double bond. Alkyl chains may be unsubstituted or substituted with from 1 to 4 substituents. Preferred substituted alkyl are mono-, di-, or trisubstituted. The substituents may be lower alkyl, halo, hydroxy, aryloxy (e.g., phenoxy), acyloxy (e.g., acetoxy), carboxy, monocyclic

5 aromatic ring (e.g., phenyl), monocyclic heteroaromatic ring, monocyclic carbocyclic aliphatic ring, monocyclic heterocyclic aliphatic ring, and amino.

"Lower alkyl" is an alkyl chain comprised of 1 to 6, preferably 1 to 3 carbon atoms.

10 "Aromatic ring" is an aromatic hydrocarbon ring. Aromatic rings are monocyclic or fused bicyclic ring systems. Monocyclic aromatic rings contain from about 5 to about 10 carbon atoms, preferably from 5 to 7 carbon atoms, and most preferably from 5 to 6 carbon atoms in the ring. Bicyclic aromatic rings contain from 8 to 12 carbon atoms, preferably 9 or 10 carbon atoms in the ring system. Bicyclic aromatic rings include ring systems wherein one ring in the system is aromatic. Preferred bicyclic aromatic rings are ring systems wherein both rings in the system are aromatic. Aromatic rings may be 15 unsubstituted or substituted with from 1 to 4 substituents on the ring. The substituents may be halo, cyano, alkyl, heteroalkyl, haloalkyl, phenyl, phenoxy or any combination thereof. Preferred substituents include halo and haloalkyl. Preferred aromatic rings include naphthyl and phenyl. The most preferred aromatic ring is phenyl.

20 "Carbocyclic aliphatic ring" is a saturated or unsaturated hydrocarbon ring. Carbocyclic aliphatic rings are not aromatic. Carbocyclic aliphatic rings are monocyclic. Carbocyclic aliphatic rings contain from about 4 to about 10 carbon atoms, preferably from 4 to 7 carbon atoms, and most preferably from 5 to 6 carbon atoms in the ring. Carbocyclic aliphatic rings may be unsubstituted or substituted with from 1 to 4 substituents on the ring. The substituents may be halo, cyano, alkyl, heteroalkyl, 25 haloalkyl, phenyl, phenoxy or any combination thereof. Preferred substituents include halo and haloalkyl. Preferred carbocyclic aliphatic rings include cyclopentyl, cyclohexyl, cyclohexenyl, cycloheptyl, and cyclooctyl. More preferred carbocyclic aliphatic rings include cyclohexyl, cycloheptyl, and cyclooctyl.

30 "Halo" is fluoro, chloro, bromo or iodo. Preferred halo are fluoro, chloro and bromo; more preferred are chloro and fluoro, especially fluoro.

35 "Haloalkyl" is a straight, branched, or cyclic hydrocarbon substituted with one or more halo substituents. Preferred haloalkyl are C₁-C₁₂; more preferred are C₁-C₆; more preferred still are C₁-C₃. Preferred halo substituents are fluoro and chloro. The most preferred haloalkyl is trifluoromethyl.

40 "Heteroalkyl" is a saturated or unsaturated chain containing carbon and at least one heteroatom, wherein no two heteroatoms are adjacent. Heteroalkyl chains contain from 1 to 18 member atoms (carbon and heteroatoms) in the chain, preferably 1 to 12, more preferably 1 to 6, more preferably still 1 to 4. Heteroalkyl chains may be straight or branched. Preferred branched heteroalkyl have one or two branches, preferably one branch. Preferred heteroalkyl are saturated. Unsaturated heteroalkyl have one or more

5 double bonds and/or one or more triple bonds. Preferred unsaturated heteroalkyl have one or two double bonds or one triple bond, more preferably one double bond. Heteroalkyl chains may be unsubstituted or substituted with from 1 to 4 substituents. Preferred substituted heteroalkyl are mono-, di-, or trisubstituted. The substituents may be lower alkyl, halo, hydroxy, aryloxy (e.g., phenoxy), acyloxy (e.g., acetoxy), carboxy, 10 monocyclic aromatic ring (e.g., phenyl), monocyclic heteroaromatic ring, monocyclic carbocyclic aliphatic ring, monocyclic heterocyclic aliphatic ring, and amino.

"Lower heteroalkyl" is a heteroalkyl chain comprised of 1 to 6, preferably 1 to 3 member atoms.

"Heteroaromatic ring" is an aromatic ring containing carbon and from 1 to about 4 heteroatoms in the ring. Heteroaromatic rings are monocyclic or fused bicyclic ring systems. Monocyclic heteroaromatic rings contain from about 5 to about 10 member atoms (carbon and heteroatoms), preferably from 5 to 7, and most preferably from 5 to 6 in the ring. Bicyclic heteroaromatic rings include ring systems wherein only one ring in the system is aromatic. Preferred bicyclic heteroaromatic rings are ring systems wherein 20 both rings in the system are aromatic. Bicyclic heteroaromatic rings contain from 8 to 12 member atoms, preferably 9 or 10 in the ring. Heteroaromatic rings may be unsubstituted or substituted with from 1 to 4 substituents on the ring. The substituents may be halo, cyano, alkyl, heteroalkyl, haloalkyl, phenyl, phenoxy or any combination thereof. Preferred substituents include halo, haloalkyl, and phenyl. Preferred monocyclic 25 heteroaromatic rings include thienyl, thiazolo, purinyl, pyrimidyl, pyridyl, and furanyl. More preferred monocyclic heteroaromatic rings include thienyl, furanyl, and pyridyl. The most preferred monocyclic heteroaromatic ring is thienyl. Preferred bicyclic heteroaromatic rings include benzo[β]thiazolyl, benzo[β]thiophenyl, quinolinyl, quinoxalinyl, benzo[β]furanyl, benzimidizolyl, benzoxazolyl, indolyl, and anthranilyl. More 30 preferred bicyclic heteroaromatic rings include benzo[β]thiazolyl, benzo[β]thiophenyl, and benzoxazolyl.

"Heteroatom" is a nitrogen, sulfur, or oxygen atom. Groups containing more than one heteroatom may contain different heteroatoms.


"Heterocyclic aliphatic ring" is a saturated or unsaturated ring containing carbon 35 and from 1 to about 4 heteroatoms in the ring, wherein no two heteroatoms are adjacent in the ring and no carbon in the ring that has a heteroatom attached to it also has a hydroxyl, amino, or thiol group attached to it. Heterocyclic aliphatic rings are not aromatic. Heterocyclic aliphatic rings are monocyclic. Heterocyclic aliphatic rings contain from about 4 to about 10 member atoms (carbon and heteroatoms), preferably from 4 to 40 7-member atoms, and most preferably from 5 to 6 member atoms in the ring.

5 Heterocyclic aliphatic rings may be unsubstituted or substituted with from 1 to 4 substituents on the ring. The substituents may be halo, cyano, alkyl, heteroalkyl, haloalkyl, phenyl, phenoxy or any combination thereof. Preferred substituents include halo and haloalkyl. Preferred heterocyclic aliphatic rings include piperzyl, morpholinyl, tetrahydrofuranyl, tetrahydropyranyl and piperdyl.

10 "Phenyl" is a monocyclic aromatic ring which may or may not be substituted with from about 1 to about 4 substituents. The substituents may be fused but not bridged and may be substituted at the *ortho*, *meta* or *para* position on the phenyl ring, or any combination thereof. The substituents may be halo, acyl, cyano, alkyl, heteroalkyl, haloalkyl, phenyl, phenoxy or any combination thereof. Preferred substituents on the phenyl ring include halo and haloalkyl. The most preferred substituent is halo. The preferred substitution pattern on the phenyl ring is *ortho* or *meta*. The most preferred substitution pattern on the phenyl ring is *meta*.

Compounds

20 The subject invention involves compounds having the following structure:



Formula A

25 In the above structure, R_1 is CO_2H , $C(O)NHOH$, CO_2R_3 , CH_2OH , $S(O)_2R_3$,
 $C(O)NHR_3$, $C(O)NHS(O)_2R_4$, or tetrazole; wherein R_3 is alkyl, heteroalkyl, carbocyclic
aliphatic ring, heterocyclic aliphatic ring, monocyclic aromatic ring, or monocyclic
heteroaromatic ring; and R_4 is alkyl, heteroalkyl, carbocyclic aliphatic ring, heterocyclic
aliphatic ring, monocyclic aromatic ring, or monocyclic heteroaromatic ring. Preferred R_3 ,
30 is methyl, ethyl, and isopropyl. Preferred R_1 is CO_2H , $C(O)NHOH$, CO_2R_3 ,
 $C(O)NHS(O)_2R_4$, and tetrazole. Most preferred R_1 is CO_2H and CO_2R_3 .

In the above structure, R_2 is H or lower alkyl. The most preferred R_2 is H.

In the above structure, X is C=C or a covalent bond


In the above structure, Z is an aromatic ring or a heteroaromatic ring provided that when Z is a heteroaromatic ring and X is a covalent bond, Z is attached to C₁₅ via a

5 Carbon member atom. When X is C≡C, preferred Z is monocyclic aromatic ring. When X is C≡C, more preferred Z is furanyl, thieryl, and phenyl. When X is a covalent bond, preferred Z is a bicyclic heteroaromatic ring.


The invention also includes optical isomers, diastereomers and enantiomers of the above structure. Thus, at all stereocenters where stereochemistry is not defined (C₁₁, 10 C₁₂, and C₁₅), both epimers are envisioned. Preferred stereochemistry at all such stereocenters of the compounds of the invention mimic that of naturally occurring PGF_{2α}.

As can be readily seen from the description above, the invention can be placed into two subgeneruses based upon the functional group "X." **Formula A1** (X is C≡C) and **Formula A2** (X is a covalent bond) below depict these two subgeneruses:

15



Formula A1



Formula A2

It has been discovered that the novel PGF analogs of the subject invention are 20 useful for treating bone disorders, especially those that require a significant increase in bone mass, bone volume, or bone strength. Surprisingly, the compounds of the subject invention have been found to provide the following advantages over known bone disorder 25 therapies: (1) An increase trabecular number through formation of new trabeculae; (2) An increase in bone mass and bone volume while maintaining a more normal bone turnover rate; and/or (3) An increase in bone formation at the endosteal surface without increasing cortical porosity.

In order to determine and assess pharmacological activity, testing of the subject 30 compounds in animals is carried out using various assays known to those skilled in the art. For example, the bone activity of the subject compounds can be conveniently demonstrated using an assay designed to test the ability of the subject compounds to increase bone volume, mass, or density. An example of such assays is the ovariectomized rat assay.


In the ovariectomized rat assay, six-month old rats are ovariectomized; aged 2 months, and then dosed once a day subcutaneously with a test compound. Upon 35 completion of the study, bone mass and/or density can be measured by dual energy x-

5 ray absorptometry (DXA) or peripheral quantitative computed tomography (pQCT), or micro computed tomography (mCT). Alternatively, static and dynamic histomorphometry can be used to measure the increase in bone volume or formation.

10 Pharmacological activity for glaucoma can be demonstrated using assays designed to test the ability of the subject compounds to decrease intraocular pressure. Examples of such assays are described in the following reference, incorporated herein: C. Liljebris, G. Selen, B. Resul, J. Sternschantz, and U. Hacksell, "Derivatives of 17-Phenyl-18,19,20-trinorprostaglandin F₂ α Isopropyl Ester: Potential Antiglaucoma Agents", Journal of Medicinal Chemistry, Vol. 38 No. 2 (1995), pp. 289-304.

15 Compounds useful in the subject invention can be made using conventional organic syntheses. A particularly preferred synthesis is the following general reaction scheme:

Scheme 1



In Scheme 1, R_1 , R_2 , X , and Z are as defined above. The methyl 7-[3-(R)-hydroxy-5-oxo-1-cyclopent-1-yl] heptanoate (**S1a**) depicted as starting material for Scheme 1 is commercially available (such as from Sumitomo Chemical or Cayman Chemical).

The C₁₁ alcohol of methyl 7-[3-(R)-hydroxy-5-oxo-1-cyclopent-1-yl] heptanoate (**S1a**) is protected with a suitable protecting group. The most preferred protecting group is a silyl group. In the above Scheme 1, methyl 7-[3-(R)-hydroxy-5-oxo-1-cyclopent-1-yl] heptanoate (**S1a**) is reacted with a silylating agent and base in a solvent that will allow the silylation to proceed. Preferred silylating agents include tert-butyldimethylsilyl chloride and tert-butyldimethylsilyl trifluoromethanesulphonate. The most preferred silylating agent is tert-butyldimethylsilyl trifluoromethanesulphonate. Preferred bases include triethylamine, trimethylamine, and 2,6-lutidine. More preferred bases include

5 triethylamine and 2,6-lutidine. The most preferred base is 2,6-lutidine. Preferred solvents include halocarbon solvents with dichloromethane being the most preferred solvent. The reaction is allowed to proceed at a temperature preferably between -100°C and 100°C, more preferably between -80°C and 80°C, and most preferably between -70°C and 23°C.

10 The resulting silylated compound is isolated by methods known to those of ordinary skill in the art. Such methods include, but are not limited to, extraction, solvent evaporation, distillation, and crystallization. Preferably, the silyl ether is purified after isolation by distillation under vacuum.

15 The silylated compound is then reacted with the cuprate generated via Grignard formation of the appropriate alkenyl bromide as disclosed, for example, in the following references: H.O. House et. al., "The Chemistry of Carbanions: A Convenient Precursor for the Generation of Lithium Organocuprates", J. Org. Chem. Vol. 40 (1975) pp. 1460-69; and P. Knochel et. al., "Zinc and Copper Carbenoids as Efficient and Selective a'd Multicoupling Reagents", J. Amer. Chem. Soc. Vol. 111 (1989) p. 6474-76. Preferred 20 alkenyl bromides include 4-bromo-1-butene, 4-bromo-1-butyne, 4-bromo-2-methyl-1-butene, and 4-bromo-2-ethyl-1-butene. The most preferred alkenyl bromide is 4-bromo-1-butene. Preferred solvents include ethereal solvents, of which diethyl ether and tetrahydrofuran are preferred. The most preferred solvent is tetrahydrofuran. The Grignard reagent is allowed to form at a temperature between 100°C and 23°C, more 25 preferably between 85°C and 30°C, and most preferably between 75°C and 65°C. The reaction time is preferably between 1 hour and 6 hours, with a more preferred reaction time being between 2 hours and 5 hours, and the most preferred reaction time being between 3 hours and 4 hours.

30 Once the Grignard reagent is formed, the cuprate is generated from the alkenyl magnesium species. The temperature range for cuprate formation is between -100°C and 0°C. The preferred temperature range is between -80°C and -20°C. The more preferred temperature range is between -75°C and -50°C. The preferred reaction time is between 30 minutes and 6 hours. The more preferred reaction time is between 45 minutes and 3 hours. The most preferred reaction time is between 1 hours and 1.5 35 hours.

35 The alkene thus formed is isolated by methods known to one of ordinary skill in the art. Such methods include, but are not limited to, extraction, solvent evaporation, distillation, and crystallization. Preferably, the alkene is purified by flash chromatography on silica gel (Merck, 230-400 mesh) using 10% EtOAc/hexanes as the eluent. The 40 alkene is then reacted with a hydride reducing agent and a polar, protic solvent to give

5 the C-9 alcohol. Preferred reducing agents include lithium aluminum hydride, sodium borohydride, and L-selectride. More preferred reducing agents include sodium borohydride, and L-selectride. The most preferred reducing agent is sodium borohydride. Preferred solvents include methanol, ethanol, and butanol. The most preferred solvent is methanol. The reduction is carried out at a temperature between -
10 100°C and 23°C. The preferred temperature range is between -60°C and 0°C. The most preferred temperature range is between -45°C and -20°C.

The resulting alcohol is isolated by methods known to one of ordinary skill in the art. Such methods include, but are not limited to, extraction, solvent evaporation, distillation, and crystallization. Preferably, the alcohol is purified by flash chromatography 15 on silica gel (Merck, 230-400 mesh) using 20% EtOAc/hexanes as the eluent.

The resultant alcohol can be protected as described previously herein. Preferred silylating agents in this case also include tert-butyldimethylsilyl chloride and tert-butyldimethylsilyl trifluoromethanesulphonate. The most preferred silylating agent is tert-butyldimethylsilyl trifluoromethanesulphonate. Preferred bases include triethylamine, 20 trimethylamine, and 2,6-lutidine. More preferred bases include triethylamine and 2,6-lutidine. The most preferred base is 2,6-lutidine. Preferred solvents include halocarbon solvents with dichloromethane being the most preferred solvent. The reaction is allowed to proceed at a temperature preferably between -100°C and 100°C, more preferably between -80°C and 80°C, and most preferably between -70°C and 23°C.

25 The resulting silylated compound is isolated by methods known to those of ordinary skill in the art. Such methods include, but are not limited to, extraction, solvent evaporation, distillation, and crystallization. Preferably, the silyl ether is purified after isolation by distillation under vacuum.

The protected or alcohol is then treated with a form of osmium, and sodium 30 periodate in a solvent where they are both soluble. Preferred forms of osmium include osmium tetroxide and potassium osmate. Preferred solvent systems include 1:1 mixtures of acetic acid and water and 1:1:2 mixtures of water, acetic acid and THF. The result of this treatment is the aldehyde, **S1b**.

The compound **S1b** is isolated by methods known to one of ordinary skill in the 35 art. Such methods include, but are not limited to, extraction, solvent evaporation, distillation, and crystallization. Preferably, **S1b** is purified by flash chromatography on silica gel (Merck, 230-400 mesh) using 20% EtOAc/hexanes as the eluent.

The key intermediate aldehyde depicted as **S1b** can be reacted with a variety 40 unsaturated carbon nucleophiles to provide the C-9 and C-11-protected 13,14-dihydro-16-tetranor prostaglandin **F1α** derivatives depicted as **S1c**.

5 With alkyne nucleophiles, the reaction is carried out preferably at between -80°C and 0°C, more preferably between -80°C and -20°C, and most preferably between -80°C and -40°C. Preferred bases for the reaction include *n*-butyl lithium, *s*-butyl lithium, *t*-butyl lithium, and lithium diisopropyl amide (LDA). Preferred solvents for the reaction are ether solvents. Preferred solvents include diethyl ether, and tetrahydrofuran. The most 10 preferred solvent is tetrahydrofuran. With heterocyclic nucleophiles, preferred solvents include ethereal solvents. More preferred ethereal solvents include diethyl ether, dibutyl ether and tetrahydrofuran. The most preferred ethereal solvent is tetrahydrofuran.

15 The resulting compounds depicted as **S1c** can then be deprotected using techniques known to one of ordinary skill in the art, and isolated yielding the 13,14-dihydro-15-substituted-15-pentanor prostaglandin $F_{1\alpha}$ derivatives depicted by **Formula I**. Compounds depicted by **Formula I** are exemplified in **Examples 1-43**.

20 Compounds depicted by **Formula II** can be made directly from the C-9 and C-11-protected 13,14-dihydro-16-tetranor prostaglandin $F_{1\alpha}$ derivatives depicted as **S1c** by methods known to one of ordinary skill in the art. For example, the condensation of methyl esters of **S1c** with amines or hydroxylamine provides compounds depicted by **Formula II**. Compounds depicted by **Formula II** are exemplified in **Examples 44-47**. These compounds are isolated by methods known to one of ordinary skill in the art. Such methods include, but are not limited to, extraction, solvent evaporation, distillation, and crystallization.

25 The following non-limiting examples illustrate the compounds, compositions, and uses of the present invention.


Examples

30 Compounds are analyzed using ^1H and ^{13}C NMR, Elemental analysis, mass spectra, high resolution mass spectra and/or IR spectra as appropriate.

35 Typically, inert solvents are used, preferably in dried form. For example, tetrahydrofuran (THF) is distilled from sodium and benzophenone, diisopropylamine is distilled from calcium hydride and all other solvents are purchased as the appropriate grade. Chromatography is performed on silica gel (70-230 mesh; Aldrich) or (230-400 mesh; Merck) as appropriate. Thin layer chromatography analysis is performed on glass mounted silica gel plates (200-300 mesh; J.T. Baker) and visualized using *uv* light, 5% phosphomolybdic acid in EtOH, or ammonium molybdate/cernic sulfate in 10% aqueous H_2SO_4 .

5

EXAMPLE 1

Preparation of 13,14-dihydro-15-(thianaphthyl) pentanor prostaglandin F₁α

10

a. **Methyl 7-(2-oxo-4-(1,1,2,2-tetramethyl-1-silapropoxy)cyclopent-1-enyl) heptanoate S2b:** To a solution of Methyl-7-[3-(R)-hydroxy-5-oxo-1-cyclopenten-1-yl] heptanoate S2a (1 equiv.) in CH₂Cl₂ at -78°C is added 2,6 Lutidine (1.3 equiv.) dropwise over 15 minutes. The solution is kept at -78°C, and TBDMS Triflate (1.2 equiv.) in CH₂Cl₂ is added-dropwise over 15 minutes. The reaction is warmed gradually to room temperature and stirred at room temperature for 15 hours. Aqueous 10% HCl is added and the layers are separated. The water layer is extracted with CH₂Cl₂ and the organic layers are combined. The organic layer is washed with brine, dried (Na₂SO₄) and concentrated. The residue is distilled under vacuum (10 mm Hg) to provide the silyl ether S2b.

b. **Methyl 7-(5-but-3-enyl-2-hydroxy-4-(1,1,2,2-tetramethyl-1-silapropoxy)cyclopentyl) heptanoate S2c:** To a slurry of Mg° powder (2 equiv.) in THF at room temperature is added one crystal of iodine (catalytic I₂) and 1-bromobutene (2 equiv.) dropwise over 10 minutes. The reaction proceeds to exotherm as the addition continues. After the addition is complete, the reaction is refluxed for 3 hours and cooled to room temperature. The Grignard is diluted with THF and added via cannula to a 3-necked flask equipped with mechanical stirring and charged with CuBr.DMS (2 equiv.) in

5 a 1:1 solution of THF/DMS at -78°C. After the addition of the Grignard (~20 min), the reaction is stirred for 1 hour at -78°C. The color of the reaction is dark red at this point. A solution of the ketone **S2b** (1 equiv.) in THF is then added dropwise over 25 minutes. The reaction is stirred at -78°C for 15 minutes, then allowed to warm slowly to room temperature over 2 hours. The reaction is quenched with aqueous NH₄Cl and the 10 excess DMS is allowed to evaporate overnight. The reaction is partitioned between brine/ CH₂Cl₂ and the layers are separated. The aqueous layer is back-extracted with CH₂Cl₂ and the organic layers are combined and dried (Na₂SO₄). The solvent is removed in vacuo and the residue is chromatographed on SiO₂ (10 % hexane/EtOAc) to give the ketone precursor to **S2c**.

15 The ketone precursor to **S2c** (1 equiv.) is dissolved in MeOH and cooled to -40°C. Sodium borohydride (0.9 equiv.) is added portionwise over 10 minutes. After the addition is complete, the reaction is stirred for 13 hours at -40°C and then for 12 hours at -78°C. The reaction is quenched with water, partitioned between brine and CH₂Cl₂, and the layers separated. The aqueous layer is back-extracted with CH₂Cl₂ and the organic 20 layers are combined and dried (Na₂SO₄). The solvent is removed in vacuo and the residue chromatographed on SiO₂ (30 % EtOAc/hexanes) to give the alcohol **S2c**.

c. **Methyl 7-(5-but-3-enyl-2,4-di(1,1,2,2-tetramethyl-1-silapropoxy)cyclopentyl) heptanoate S2d:** The alcohol **S2c** (1 equiv.) is dissolved in CH₂Cl₂ and 25 cooled to 0°C and added is 2,6 lutidine (1.3 equiv.) dropwise over 15 minutes. The solution is kept at -78°C, and TBDMS Triflate (1.2 equiv.) in CH₂Cl₂ is added dropwise over 15 minutes. The reaction is warmed gradually to room temperature and stirred at room temperature for 15 hours. Aqueous 10% HCl is added and the layers are separated. The water layer is extracted with CH₂Cl₂ and the organic layers are 30 combined. The organic layer is washed with brine, dried (Na₂SO₄) and concentrated. The residue is chromatographed (10% EtOAc in hexanes) to provide the silyl ether **S2d**.

d. **Methyl 7-(5-(3-oxopropyl)-2,4-di(1,1,2,2-tetramethyl-1-silapropoxy)cyclopentyl) heptanoate S2e:** In a 50 mL round-bottomed flask, Sodium periodate (2 equiv.) and 10 mL of water are added. This is stirred until the periodate has completely 35 dissolved. Then an equal portion of glacial acetic acid is added, followed by two portions of tetrahydrofuran. Finally, a few mole percent of potassium osmate are added, followed by the alkene **S2d** (1 equiv.). The reaction is stirred at room temperature under nitrogen with TLC being used to monitor the reaction. When no starting material is evident by 40 TLC, The reaction is quenched with brine and is extracted with ethyl acetate and

5 hexanes in a 4:1 ratio. The organic layer is washed with brine to neutral pH, dried over sodium sulfate, and concentrated. After column chromatography, (7:3, Hexane: Ethyl Acetate) S2e is obtained.

10 e. **Methyl 7-(5-(3-hydroxy-3-thianaphthyl-propanyl)-2,4-di(1,1,2,2-tetramethyl-1-silapropoxy) cyclopentyl) heptanoate S2f:** The aldehyde S2e is dissolved in a few mL of dry THF and is added dropwise to a -78 °C THF solution of the lithium anion of thianaphthylene (prepared by combining *n*-butyl lithium and thianaphthylene at -78°C.) a 50 mL round-bottomed flask. This is stirred until the reaction has ceased to progress as evidenced by TLC. Then the reaction is quenched at -78 °C with a saturated solution of 15 ammonium chloride and is extracted with ethyl acetate and hexanes in a 4:1 ratio. The organic layer is washed with brine to neutral pH, dried over sodium sulfate, and concentrated. After column chromatography, (7:3, Hexane: Ethyl Acetate) S2f is obtained.

20 f. **13,14-dihydro-15-(thianaphthyl)-15-pentanor prostaglandin F_{1α} (S2g):** To a small round-bottomed flask, is added methyl ester S2f and 3 mL of CH₃CN and 0.1 mL of HF/Pyridine (0.1 mmol, 1 equiv.) are added while the flask is warmed from 0°C to room temperature. After 3 hours at 21°C, the reaction is quenched with saturated aqueous NaCl. The aqueous layer is extracted three times with CH₂Cl₂. The organic layers are 25 combined and washed three time with 1N HCl, brine, and dried (Na₂SO₄). After column chromatography, (7:3, Hexane: Ethyl Acetate) a clear oil is obtained. This oil is added to a few mL of a 3:1 THF: water solution, and the flask is cooled to 0°C. An excess amount (2.5 equiv.) of lithium hydroxide is added, the ice bath is removed, and the reaction is stirred at room temperature overnight. Methylene chloride and saturated citric acid are 30 added to the reaction mixture, the aqueous layer is washed 3 times with methylene chloride, the organic layers are combined and washed with brine, dried (Na₂SO₄), concentrated *in vacuo*, and the residue is chromatographed (methylene chloride, methanol, acetic acid, 9.6, 0.4, 0.015), to provide S2g.

Examples 2-22


Examples 2-22 are prepared using substantially the same procedures as those described in Example 1, substituting the appropriate starting materials. The skilled artisan may change temperature, pressure, atmosphere, solvents or the order of reactions as appropriate. Additionally, the skilled artisan may use protecting groups to 40 block side reactions or increase yields as appropriate. All such modifications can readily

5 be carried out by the skilled artisan in the art of organic chemistry, and thus are within the scope of the invention.

Example 2

13,14-dihydro-15-(2-benzathiozoly)-15-pentanor Prostaglandin F_{1α}


10



Example 3

13,14-dihydro-15-(7-fluorobenzathiozoly)-15-pentanor Prostaglandin F_{1α}


15



Example 4


13,14-dihydro-16-ynyl-17-(2,5-difluorophenyl)-17-trinor Prostaglandin F_{1α}

20




Example 5

13,14-dihydro-16-ynyl-17-(2,3-difluorophenyl)-17-trinor Prostaglandin F_{1α}




Example 6

13,14-dihydro-16-ynyl-17-(3,5-difluorophenyl)-17-trinor Prostaglandin F 1α




Example 7

13,14-dihydro-16-ynyl-17-(3,4-difluorophenyl)-17-trinor Prostaglandin F 1α



Example 8

13,14-dihydro-15-(6-fluorothianaphthyl)-15-pentanor Prostaglandin F 1α




Example 9


13,14-dihydro-16-ynyl-17-(2,4-difluorophenyl)-17-trinor Prostaglandin F 1α

18


5




5

Example 10**13,14-dihydro-16-ynyl-17-(3-fluorophenyl)-17-trinor Prostaglandin F1 α methyl ester**


10

Example 11**13,14-dihydro-16-ynyl-17-(2-fluoro-4-methylphenyl)-17-trinor Prostaglandin F1 α** 


15

Example 12**13,14-dihydro-16-ynyl-17-(4-chlorophenyl)-17-trinor Prostaglandin F1 α** 


20

Example 13**13,14-dihydro-16-ynyl-17-phenyl-17-trinor Prostaglandin F1 α isopropyl ester**


5

Example 14**13,14-dihydro-16-ynyl-17-(4-fluorophenyl)-17-trinor Prostaglandin F1 α ethyl ester**


10 **13,14-dihydro-15-(5-fluorobenzothiazolyl)-15-pentanor Prostaglandin F1 α isopropyl ester**




15 **13,14-dihydro-16-ynyl-17-(2-chlorophenyl)-17-trinor Prostaglandin F1 α**




20 **13,14-dihydro-16-ynyl-17-(2-fluorophenyl)-17-trinor Prostaglandin F1 α methyl ester**




5

Example 18**13,14-dihydro-16-ynyl-17-(2-fluorophenyl)-17-trinor Prostaglandin F1 α** 

10


Example 19**13,14-dihydro-16-ynyl-17-(4-phenylphenyl)-17-trinor Prostaglandin F1 α** 

15

Example 20**13,14-dihydro-16-ynyl-18-phenyl-18-dinor Prostaglandin F1 α** 


20

Example 21**13,14-dihydro-16-ynyl-17-(4-methylphenyl)-17-trinor Prostaglandin F1 α**




5

Example 22

13,14-dihydro-16-ynyl-18-(2-fluorophenyl)-18-dinor Prostaglandin F1 α 

10

Example 23

Preparation of 13,14-dihydro-15-phenyl-15-pentanor prostaglandin F1 α :

15 a. Methyl 7-(5-(3-hydroxy,3-phenyl-propanyl)-2,4-di(1,1,2,2-tetramethyl-1-silapropoxy) cyclopentyl) heptanoate S3a: The aldehyde S2e from Example 1 is dissolved in a few mL of dry THF and is added dropwise to a -78 °C THF solution of the Grignard species (prepared by combining Magnesium and bromobenzene at 0°C.) a 50 mL round-bottomed flask. This is stirred until the reaction has ceased to progress as evidenced by TLC. Then the reaction is quenched at -78 °C with a saturated solution of ammonium chloride and is extracted with ethyl acetate and hexanes in a 4:1 ratio. The organic layer is washed with brine to neutral pH, dried over sodium sulfate, and

20

5 concentrated. After column chromatography, (7:3, Hexane: Ethyl Acetate) S3a is obtained.


b. **13,14-dihydro-15-phenyl-15-pentanor prostaglandin F_{1α} (S3b):** To a small round-bottomed flask, is added methyl ester S3a and 3 mL of CH₃CN and 0.1 mL of HF/Pyridine (0.1 mmol, 1 equiv.) are added while the flask is warmed from 0°C to room temperature. After 3 hours at 21°C, the reaction is quenched with saturated aqueous NaCl. The aqueous layer is extracted three times with CH₂Cl₂. The organic layers are combined and washed three time with 1N HCl, brine, and dried (Na₂SO₄). After column chromatography, (97:3,dichloromethane:methanol) a clear oil is obtained. This oil is added to a few mL of a 3:1 THF: water solution, and the flask is cooled to 0°C. An excess amount (2.5 equiv.) of lithium hydroxide is added, the ice bath is removed, and the reaction is stirred at room temperature overnight. Methylene chloride and saturated citric acid are added to the reaction mixture, the aqueous layer is washed 3 times with methylene chloride, the organic layers are combined and washed with brine, dried (Na₂SO₄), concentrated *in vacuo*, and the residue is chromatographed (methylene chloride, methanol, acetic acid, 9.6, 0.4, 0.015), to provide S3b.

Examples 24-35

Examples 24-35 are prepared using substantially the same procedures as those described in Example 23, substituting the appropriate starting materials. The skilled artisan may change temperature, pressure, atmosphere, solvents or the order of reactions as appropriate. Additionally, the skilled artisan may use protecting groups to block side reactions or increase yields as appropriate. All such modifications can readily be carried out by the skilled artisan in the art of organic chemistry, and thus are within the scope of the invention.


Example 24

13,14-dihydro-15-(4-methylphenyl)-15-pentanor Prostaglandin F_{1α}




5

Example 25

13,14-dihydro-15-(4-trifluoromethylphenyl)-15-pentanor Prostaglandin F₁α


10

Example 26

13,14-dihydro-15-(3-trifluoromethylphenyl)-15-pentanor Prostaglandin F₁α

15

Example 27


13,14-dihydro-15-(2-fluorophenyl)-15-pentanor Prostaglandin F₁α

20

Example 28


13,14-dihydro-15-(3,5-difluorophenyl)-15-pentanor Prostaglandin F₁α ethyl ester

26




5


5

Example 29**13,14-dihydro-15-(3-chloro-4-fluoro-6-methylphenyl)-15-pentanor Prostaglandin F₁** α 


10

Example 30**13,14-dihydro-15-(3-pyridinyl)-15-pentanor Prostaglandin F₁ α** 


15

Example 31**13,14-dihydro-15-(2-chlorophenyl)-15-pentanor Prostaglandin F₁ α** 


20

Example 32**13,14-dihydro-15-(4-phenylphenyl)-15-pentanor Prostaglandin F₁ α** 


5

Example 33**13,14-dihydro-15-S- (2-fluorophenyl)-15-pentanor Prostaglandin F₁α**

10

Example 34**13,14-dihydro-15-S- (2-fluoronaphthyl)-15-pentanor Prostaglandin F₁α**


15

Example 35**13,14-dihydro-15- (2-fluoro-4-pyridyl)-15-pentanor Prostaglandin F₁α isopropyl ester**

5

Example 36

Preparation of 13,14-dihydro-15-(6-methylnaphth-2-yl)-15-pentanor prostaglandin F_{1α}:



10

a. **Methyl 7-(5-(3-hydroxy,(4-methyl-2-naphthyl)-propanyl)-2,4-di(1,1,2,2-tetramethyl-1-silapropoxy) cyclopentyl) heptanoate S4a:** The aldehyde S2e from Example 1 is dissolved in a few mL of dry THF and is added dropwise to a -78 °C THF solution of naphthyl anion (prepared by t-butyl Lithium and the naphthyl bromide at -78°C.) a 50 mL round-bottomed flask. This is stirred until the reaction has ceased to progress as evidenced by TLC. Then the reaction is quenched at -78 °C with a saturated solution of ammonium chloride and is extracted with ethyl acetate and hexanes in a 4:1 ratio. The organic layer is washed with brine to neutral pH, dried over sodium sulfate, and concentrated. After column chromatography, (7:3, Hexane: Ethyl Acetate) S4a is obtained.

b. **13,14-dihydro-16,17-dehydro-15-(6-methyl-2-naphthyl)-15-pentanor prostaglandin F_{1α} (S4b):** To a small round-bottomed flask, is added methyl ester S4a and 3 mL of CH₃CN and 0.1 mL of HF/Pyridine (0.1 mmol, 1 equiv.) are added while the flask is warmed from 0°C to room temperature. After 3 hours at 21°C, the reaction is quenched with saturated aqueous NaCl. The aqueous layer is extracted three times with CH₂Cl₂. The organic layers are combined and washed three time with 1N HCl, brine, and

5 dried (Na₂SO₄). After column chromatography, (97:3,dichlormethane:methanol) a clear oil is obtained. This oil is added to a few mL of a 3:1 THF: water solution, and the flask is cooled to 0°C. An excess amount (2.5 equiv.) of lithium hydroxide is added, the ice bath is removed, and the reaction is stirred at room temperature overnight. Methylene chloride and saturated citric acid are added to the reaction mixture, the aqueous layer is
10 washed 3 times with methylene chloride, the organic layers are combined and washed with brine, dried (Na₂SO₄), concentrated *in vacuo*, and the residue is chromatographed (methylene chloride, methanol, acetic acid, 9.6, 0.4, 0.015), to provide S4b.


Examples 37-42

15 Examples 37-42 are prepared using substantially the same procedures as those described in Example 36, substituting the appropriate starting materials. The skilled artisan may change temperature, pressure, atmosphere, solvents or the order of reactions as appropriate. Additionally, the skilled artisan may use protecting groups to block side reactions or increase yields as appropriate. All such modifications can readily
20 be carried out by the skilled artisan in the art of organic chemistry, and thus are within the scope of the invention.

Example 37

13,14-dihydro-15-(benzo[b]thiophen-5-yl)-15-pentanor prostaglandin F_{1α}


25




Example 38

13,14-dihydro-15-(6-benzothiazol-5-yl)-15-pentanor prostaglandin F_{1α}


30




5

Example 39**13,14-dihydro-15-(benzo[b]furan-5-yl)-15-pentanor prostaglandin F₁₀ methyl ester**


10

Example 40**13,14-dihydro-15-(5-fluoronaphthyl)-15-pentanor prostaglandin F₁₀**

15

Example 41**13,14-dihydro-15-(8-fluoro-2-naphthyl)-15-pentanor prostaglandin F₁₀**


-20-

13,14-dihydro-15-(8-trifluoromethyl-2-naphthyl)-15-pentanor prostaglandin F₁₀

5

Example 43


13,14-dihydro-15-(1-fluoro-3-trifluoromethyl-2-naphthyl)-15-pentanor prostaglandin F_{1α} isopropyl ester



10

Example 44

Preparation of 13,14-dihydro-16-ynyl-17-(2-fluorophenyl)-17-trinor Prostaglandin F1α 1-hydroxamic acid:



15

In a flame-dried 25 mL round-bottomed flask equipped with a magnetic stir bar is placed 13,14-dihydro-16,17-didehydro-17-o-fluorophenyl trinor Prostaglandin F1α methyl ester (Example 17) (1.0 equiv.) in methanol. To this solution is added hydroxylamine in methanol (1.25 equiv.). The solution stirred for a few minutes. The solution is then treated with 1N hydrochloric acid and extracted with ethyl acetate. The organic layer is washed with brine, dried over anhydrous MgSO₄, filtered and concentrated under reduced pressure. The residue is purified by chromatography to give 13,14-dihydro-16,17-didehydro-17-o-fluorophenyl trinor Prostaglandin F1α 1-hydroxamic acid.

25


Examples 45-47 are prepared using substantially the same procedures as those described in Example 44, substituting the appropriate starting materials. The skilled artisan may change temperature, pressure, atmosphere, solvents or the order of reactions as appropriate. Additionally, the skilled artisan may use protecting groups to block side reactions or increase yields as appropriate. All such modifications can readily be carried out by the skilled artisan in the art of organic chemistry, and thus are within the scope of the invention.

Examples 45-47

5

Example 45


13,14-dihydro-15-(benzothiozolyl)-15-pentanor Prostaglandin F₁α 1-hydroxamic acid



10

Example 46


13,14-dihydro-15-(5-fluorothianaphthyl)-15-pentanor Prostaglandin F₁α 1-hydroxamic acid



15

Example 47

13,14-dihydro-15-thianaphthyl-15-pentanor Prostaglandin F₁α 1-N-methanesulfonamide



20

Compositions

Compositions of the subject invention comprise a safe and effective amount of the subject compounds, and a pharmaceutically-acceptable carrier. As used herein, "safe and effective amount" means an amount of a compound sufficient to significantly induce 25 a positive modification in the condition to be treated, but low enough to avoid serious side effects (at a reasonable benefit/risk ratio), within the scope of sound medical judgment. A safe and effective amount of a compound will vary with the particular condition being

5 treated, the age and physical condition of the patient being treated, the severity of the condition, the duration of the treatment, the nature of concurrent therapy, the particular pharmaceutically-acceptable carrier utilized, and like factors within the knowledge and expertise of the attending physician.

In addition to the compound, the compositions of the subject invention contain a 10 pharmaceutically-acceptable carrier. The term "pharmaceutically-acceptable carrier", as used herein, means one or more compatible solid or liquid filler diluents or encapsulating substances which are suitable for administration to a subject. The term "compatible", as used herein, means that the components of the composition are capable of being commingled with the compound, and with each other, in a manner such that there is no 15 interaction which would substantially reduce the pharmaceutical efficacy of the composition under ordinary use situations. Pharmaceutically-acceptable carriers must, of course, be of sufficiently high purity and sufficiently low toxicity to render them suitable for administration to the subject being treated.

Some examples of substances which can serve as pharmaceutically-acceptable 20 carriers or components thereof are sugars, such as lactose, glucose and sucrose; starches, such as cornstarch and potato starch; cellulose and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose, cellulose acetate; powdered tragacanth; malt; gelatin; talc; solid lubricants, such as stearic acid, magnesium stearate; calcium sulfate; vegetable oils, such as peanut oil, cottonseed oil, sesame oil, olive oil, corn oil 25 and oil of theobroma; polyols such as propylene glycol, glycerin, sorbitol, mannitol, and polyethylene glycol; alginic acid; emulsifiers, such as the Tweens®; wetting agents such as sodium lauryl sulfate; coloring agents; flavoring agents, excipients; tableting agents; stabilizers; antioxidants; preservatives; pyrogen-free water; isotonic saline; and phosphate buffer solutions.

30 The choice of a pharmaceutically-acceptable carrier to be used in conjunction with a compound is basically determined by the way the compound is to be administered. The compounds of the present invention may be administered systemically. Routes of administration include transdermal; oral; parenterally, including subcutaneous or intravenous injection; topical; and/or intranasal.

35 The appropriate amount of the compound to be used may be determined by routine experimentation with animal models. Such models include, but are not limited to the intact and ovariectomized rat models, the ferret, canine, and non human primate models as well as disuse models.

Preferred unit dosage forms for injection include sterile solutions of water, 40 physiological saline, or mixtures thereof. The pH of said solutions should be adjusted to

5 about 7.4. Suitable carriers for injection or surgical implants include hydrogels, controlled- or sustained release devices, polylactic acid, and collagen matrices.

Suitable pharmaceutically-acceptable carriers for topical application include those suited for use in lotions, creams, gels and the like. If the compound is to be administered perorally, the preferred unit dosage form is tablets, capsules and the like.

10 The pharmaceutically-acceptable carriers suitable for the preparation of unit dosage forms for oral administration are well-known in the art. Their selection will depend on secondary considerations like taste, cost, and shelf stability, which are not critical for the purposes of the subject invention, and can be made without difficulty by those skilled in the art.

15

Methods of Use

The compounds of the present invention are useful in treating many medical disorders, including for example, ocular disorders, hypertension, fertility control, nasal congestion, neurogenic bladder disorder, gastrointestinal disorders, dermatological 20 disorders, and osteoporosis.

The compounds of the present invention are useful in increasing bone volume and trabecular number through formation of new trabeculae, bone mass while maintaining a normalized bone turnover rate, and formation at the endosteal surface without removing bone from the existing cortex. Thus, these compounds are useful in 25 the treatment and prevention of bone disorders.

The preferred routes of administration for treating bone disorders are transdermal and intranasal. Other preferred routes of administration include rectal, sublingual, and oral.

30 The dosage range of the compound for systemic administration is from about 0.01 to about 1000 µg/kg body weight, preferably from about 0.1 to about 100 µg/kg per body weight, most preferably form about 1 to about 50 µg/kg body weight per day. The transdermal dosages will be designed to attain similar serum or plasma levels, based upon techniques known to those skilled in the art of pharmacokinetics and transdermal 35 formulations. Plasma levels for systemic administration are expected to be in the range of 0.01 to 100 nanograms/ml, more preferably from 0.05 to 50 ng/ml, and most preferably from 0.1 to 10 ng/ml. While these dosages are based upon a daily administration rate, weekly or monthly accumulated dosages may also be used to calculate the clinical requirements.

5 Dosages may be varied based on the patient being treated, the condition being treated, the severity of the condition being treated, the route of administration, etc. to achieve the desired effect.

10 The compounds of the present invention are also useful in decreasing intraocular pressure. Thus, these compounds are useful in the treatment of glaucoma. The preferred route of administration for treating glaucoma is topically.

Composition and Method Examples

15 The following non-limiting examples illustrate the subject invention. The following composition and method examples do not limit the invention, but provide guidance to the skilled artisan to prepare and use the compounds, compositions and methods of the invention. In each case other compounds within the invention may be substituted for the example compound shown below with similar results. The skilled practitioner will appreciate that the examples provide guidance and may be varied based on the condition being treated and the patient.

20

Example A

Pharmaceutical compositions in the form of tablets are prepared by conventional methods, such as mixing and direct compaction, formulated as follows:

	<u>Ingredient</u>	<u>Quantity (mg per tablet)</u>
25	Compound of Example 1	5
	Microcrystalline Cellulose	100
	Sodium Starch Glycollate	30
	Magnesium Stearate	3

30 When administered orally once daily, the above composition substantially increases bone volume in a patient suffering from osteoporosis.

Example B

35 Pharmaceutical compositions in liquid form are prepared by conventional methods, formulated as follows:

<u>Ingredient</u>	<u>Quantity</u>
Compound of Example 32	1 mg
Phosphate buffered physiological saline	10 ml
Methyl Paraben	0.05ml

5 When 1.0 ml of the above composition is administered subcutaneously once daily, the above composition substantially increases bone volume in a patient suffering from osteoporosis.

Example C


10 Topical pharmaceutical compositions for lowering intraocular pressure are prepared by conventional methods and formulated as follows:

	<u>Ingredient</u>	<u>Amount (wt %)</u>
	Compound of Example 1	0.004
	Dextran 70	0.1
15	Hydroxypropyl methylcellulose	0.3
	Sodium Chloride	0.77
	Potassium chloride	0.12
	Disodium EDTA (Eddate disodium)	0.05
	Benzalkonium chloride	0.01
20	HCL and/or NaOH	pH 7.2-7.5
	Purified water	q.s. to 100%

While particular embodiments of the subject invention have been described, it would be obvious to those skilled in the art that various changes and modifications to the 25 compositions disclosed herein can be made without departing from the spirit and scope of the invention. It is intended to cover, in the appended claims, all such modifications that are within the scope of this invention.

What is claimed is:

1. A compound having the structure:



characterized in that

- (a) R₁ is selected from the group consisting of CO₂H, C(O)NHOH, CO₂R₃, CH₂OH, S(O)₂R₃, C(O)NHR₃, C(O)NHS(O)₂R₄, and tetrazole; characterized in that R₃ is alkyl, heteroalkyl, carbocyclic aliphatic ring, heterocyclic aliphatic ring, monocyclic aromatic ring, or monocyclic heteroaromatic ring; and R₄ is alkyl, heteroalkyl, carbocyclic aliphatic ring, heterocyclic aliphatic ring, monocyclic aromatic ring, or monocyclic heteroaromatic ring;
- (b) R₂ is H or lower alkyl;
- (C) X is:
 - (1) C≡C, or
 - (2) a covalent bond;
- (d) Z is an aromatic ring or a heteroaromatic ring provided that when Z is a heteroaromatic ring and X is a covalent bond, Z is attached to C₁₅ via a Carbon member atom; and
- (e) any optical isomer, diastereomer, enantiomer of the above structure or a pharmaceutically-acceptable salt, or bio-hydrolyzable amide, ester, or imide thereof.

- 2. A compound according to Claim 1 characterized in that Z is monocyclic.
- 3. A compound according to Claim 1 characterized in that Z is a bicyclic heteroaromatic ring.
- 4. A compound according to any of the preceding claims characterized in that R₁ is CO₂H, C(O)NHOH, CO₂R₃, C(O)NHS(O)₂R₄, or tetrazole.
- 5. A compound according to any of the preceding claims characterized in that R₂ is H.
- 6. A compound according to any of the preceding claims characterized in that X is C≡C.

7. A compound according to any of the preceding claims characterized in that Z substituted with one substituent, said one substituent being selected from the group consisting of: lower alkyl, halo, and haloalkyl.
8. The use of a compound according to any of the preceding claims in the manufacture of a medicament for treating a bone disorder.
9. The use according to claim 8 characterized in that the bone disorder is osteoporosis.
10. The use of a compound according to Claims 1, 2, 3, 4, 5, 6, or 7 in the manufacture of a medicament for treating glaucoma.

INTERNATIONAL SEARCH REPORT

Int'l. Appl. No.
PCT/US 00/05301

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07C405/00 //A61K31/557

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C07C A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	WO 99 12551 A (PROCTER & GAMBLE) 18 March 1999 (1999-03-18) claims 1,12,15-18	1-10
P, X	WO 99 12550 A (DELONG MITCHELL ANTHONY ;LUNDY MARK WALDEN (US); HARTKE JAMES RICH) 18 March 1999 (1999-03-18) claims 1,12,13,16-23	1-10
P, X	WO 99 12895 A (PROCTER & GAMBLE) 18 March 1999 (1999-03-18) claims 1,2,8,9	1-10
P, X	WO 99 12896 A (PROCTER & GAMBLE) 18 March 1999 (1999-03-18) claims 1,2,9,10	1-10
		-/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *U* document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

14 July 2000

Date of mailing of the International search report

21/07/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Berte, M

INTERNATIONAL SEARCH REPORT

Int'l. Application No.

PCT/US 00/05301

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,A	WO 99 12898 A (PROCTER & GAMBLE) 18 March 1999 (1999-03-18) claims ---	1-10
P,X	WO 99 12899 A (PROCTER & GAMBLE) 18 March 1999 (1999-03-18) page 1, paragraph 3; claims 1,2 ---	1-10
X	WO 97 23225 A (ALCON LAB INC) 3 July 1997 (1997-07-03) See compound IV page 10, line 5 -page 11, line 13; claims ---	1-10
X	US 3 966 792 A (HAYASHI MASAKI ET AL) 29 June 1976 (1976-06-29) claims ---	1-8
X	US 4 011 262 A (HESS HANS-JURGEN E ET AL) 8 March 1977 (1977-03-08) cited in the application column 34, line 45 - line 52 ---	1-8
X	WO 96 36599 A (ALLERGAN INC) 21 November 1996 (1996-11-21) claims 1,2,52-54 ---	1-10

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int'l. Jnlcl Application No
PCT/US 00/05301

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9912551 A	18-03-1999	AU 9219298 A		29-03-1999
		NO 20001171 A		09-05-2000
		ZA 9808228 A		09-03-1999
WO 9912550 A	18-03-1999	AU 9130298 A		29-03-1999
		NO 20001172 A		08-05-2000
		ZA 9808229 A		09-03-1999
WO 9912895 A	18-03-1999	AU 9219398 A		29-03-1999
		EP 1012136 A		28-06-2000
		NO 20001141 A		04-05-2000
		US 5977173 A		02-11-1999
		ZA 9808230 A		09-03-1999
WO 9912896 A	18-03-1999	AU 9219498 A		29-03-1999
		NO 20001142 A		04-05-2000
		ZA 9808231 A		09-03-1999
WO 9912898 A	18-03-1999	AU 9224098 A		29-03-1999
		EP 1012137 A		28-06-2000
		NO 20001139 A		04-05-2000
		ZA 9808232 A		09-03-1999
WO 9912899 A	18-03-1999	AU 9305898 A		29-03-1999
WO 9723225 A	03-07-1997	AU 7680096 A		17-07-1997
US 3966792 A	29-06-1976	JP 1134074 C		14-02-1983
		JP 49109353 A		17-10-1974
		JP 57020305 B		27-04-1982
		AU 6608974 A		28-08-1975
		BE 811665 A		17-06-1974
		DE 2409460 A		29-08-1974
		FR 2218899 A		20-09-1974
		GB 1464916 A		16-02-1977
		NL 7402663 A		30-08-1974
		ZA 7401286 A		26-02-1975
US 4011262 A	08-03-1977	AR 209064 A		31-03-1977
		AR 214383 A		15-06-1979
		AT 367033 B		25-05-1982
		AT 620773 A		15-10-1981
		AT 366060 B		10-03-1982
		AT 987276 A		15-07-1981
		AT 352920 B		10-10-1979
		AT 987476 A		15-03-1979
		AT 359659 B		25-11-1980
		AT 987676 A		15-04-1980
		AU 5778473 A		09-01-1975
		BE 802231 A		14-01-1974
		CA 1041495 A		31-10-1978
		CH 593275 A		30-11-1977
		CH 593963 A		30-12-1977
		CH 593991 A		30-12-1977
		CH 593932 A		30-12-1977
		CH 593254 A		30-11-1977
		CS 201027 B		31-10-1980
		CS 201028 B		31-10-1980

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int'l Application No
PCT/US 00/05301

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
US 4011262 A		CS	201029 B	31-10-1980
		CS	201030 B	31-10-1980
		OD	109210 A	20-10-1974
		DO	116459 A	20-11-1975
		DE	2353159 A	13-03-1975
		DE	2365767 A	15-04-1976
		DE	2334945 A	07-03-1974
		OK	137179 A	03-04-1979
		OK	137479 A	03-04-1979
		ES	416865 A	01-03-1976
		ES	437037 A	01-01-1977
		ES	437038 A	01-01-1977
		ES	437039 A	01-01-1977
		F1	57583 B	30-05-1980
		F1	790070 A	10-01-1979
		F1	790071 A	10-01-1979
		F1	790072 A	10-01-1979
		FR	2192834 A	15-02-1974
		FR	2361381 A	10-03-1978
		FR	2361410 A	10-03-1978
		G8	1446342 A	18-08-1976
		G8	1446343 A	18-08-1976
		G8	1446344 A	18-08-1976
		GB	1446341 A	18-08-1976
		HU	171156 8	28-11-1977
		HU	171158 B	28-11-1977
		HU	171946 B	28-04-1978
		HU	172058 8	28-05-1978
		IE	37909 8	09-11-1977
-----	-----	-----	-----	-----
WO 9636599 A	21-11-1996	AU	693698 8	02-07-1998
		AU	5792496 A	29-11-1996
		CA	2221110 A	21-11-1996
		EP	0825980 A	04-03-1998
		JP	11505802 T	25-05-1999
		US	5834498 A	10-11-1998
-----	-----	-----	-----	-----

THIS PAGE BLANK (USPTO)